May 2024: Imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, has been approved by the Food and Drug Administration for use in adults with low- to intermediate-1...
April 2024: The Food and Drug Administration (FDA) granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.). This approval is specifically for patients aged 6 months and ...
Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients The Food and Drug Administration has approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a ...
March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be used in adult patients with FRα positive, ...
Iovance Biotherapeutics' first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of blood cancer are treated, can now be used dir...
The Food and Drug Administration authorized nirogacestat (OGSIVEO, SpringWorks Therapeutics, Inc.) on November 27, 2023, for adult patients with advancing desmoid tumors needing systemic treatment. T...
The FDA has authorized enzalutamide for the treatment of non-metastatic castration-sensitive prostate cancer in cases of biochemical recurrence.The Food and Drug Administration approved enzalutamide ...
On October 31, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin to treat biliary tract carcinoma (BTC) that has spread or is l...
In October 2023, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine as the first-line treatment for people with locally advanced nasopharyngeal canc...
Feb 2024: Mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) therapy have shown potential in treating knee osteoarthritis (KOA) in China. A meta-analysis of randomized controlled studies lo...